TY - JOUR
AB - Reactions 2069, p124 - 26 Jul 2025 Treatment failure: case report A 44-year-old woman exhibited treatment failure during treatment with cytarabine/daunorubicin for acute myeloid leukaemia [AML; route and dosage not stated]. The woman was recently diagnosed with diabetes insipidus (DI) followed by EVI1-AML, found to have PRDM16 overexpression by t(1;2). She was started on induction therapy with cytarabine/daunorubicin [CPX-351]. However, the treatment failed to achieve disease control. Thus, she started treatment with decitabine/venetoclax, which resulted in bone marrow blast reduction to 20%. Eventually, she was hospitalised and underwent an allogeneic stem cell transplantation, which resulted in haematologic and molecular remission, with control of the DI. List J, et al. Genocopy of EVI1-AML with Paraneoplastic Diabetes Insipidus: PRDM16 Overexpression By t(1;2) and Enhancer Hijacking. Blood 144 (Suppl. 1): 6136-6137, Nov 2024. Available from: URL: https://dx.doi.org/10.1182/blood-2024-203866 [abstract] 803903304 
TI - Cytarabine/daunorubicin
JO - Reactions Weekly
DO - 10.1007/s40278-025-86782-8
DA - 2025-07-01
UR - https://www.deepdyve.com/lp/springer-journals/cytarabine-daunorubicin-XwEtFF8sCh
SP - 124
EP - 124
VL - 2069
IS - 1
DP - DeepDyve
ER -